K & B Company Inc.
Letter data
- Company
- K & B Company Inc.
- Recipient
- Brent A. Bischoff | President | K & B Company Inc. | K & B Company Inc. | 109 Arnold St. | Gallup | , | NM | 87301 | United States
- Issue date
- 2018-09-12
- Posted date
- Not available
- FDA office
- Office of Human and Animal Foods-Division IV West
- Subject
- Not available
- Product
- Not available
- CMS ID
- 528522
- Reference number
- Not available
- FEI
- Not available
- Inspection dates
- Not available
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
K & B Company Inc.
MARCS-CMS 528522 —
September 12, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
UPS Overnight
Recipient:
Recipient Name
Brent A. Bischoff
Recipient Title
President
K & B Company Inc.
K & B Company Inc.
109 Arnold St.
Gallup
,
NM
87301
United States
Issuing Office:
Office of Human and Animal Foods-Division IV West
United States
September 12, 2018
WARNING LETTER CLOSE-OUT
VIA UPS overnight
Brent A. Bischoff
President
K & B Company Inc.
109 Arnold St.
Gallup, NM 87301
Dear Mr. Bischoff:
The Food and Drug Administration has completed an evaluation of K & B Company's corrective actions in response to our Warning Letter HAF4W(DEN)-17-09-WL (DR) dated July 5, 2017. Based on our evaluation, it appears that you have addressed the violation(s) contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
LaTonya M. Mitchell
District Director, FDA Denver District
Program Division Director
Office of Human and Animal Foods - Division IV West
Content current as of:
10/01/2018